|
BE640616A
(cg-RX-API-DMAC10.html)
|
1962-12-19 |
|
|
|
|
US3492397A
(en)
|
1967-04-07 |
1970-01-27 |
Warner Lambert Pharmaceutical |
Sustained release dosage in the pellet form and process thereof
|
|
US4060598A
(en)
|
1967-06-28 |
1977-11-29 |
Boehringer Mannheim G.M.B.H. |
Tablets coated with aqueous resin dispersions
|
|
US3538214A
(en)
|
1969-04-22 |
1970-11-03 |
Merck & Co Inc |
Controlled release medicinal tablets
|
|
US4173626A
(en)
|
1978-12-11 |
1979-11-06 |
Merck & Co., Inc. |
Sustained release indomethacin
|
|
GB9404485D0
(en)
|
1994-03-09 |
1994-04-20 |
Cancer Res Campaign Tech |
Benzamide analogues
|
|
AT401651B
(de)
|
1994-06-14 |
1996-11-25 |
Biochemie Gmbh |
7-(2-(2-aminothiazol-4-yl)-2-(z)- hydroximinoacetamido)-3-n,n- dimethylcarbamoyloxymethyl-3-cephem-4-
|
|
DK0841924T3
(da)
|
1995-08-02 |
2003-02-10 |
Univ Newcastle Ventures Ltd |
Benzimidazolforbindelser
|
|
JP2002515488A
(ja)
|
1998-05-15 |
2002-05-28 |
ギルフォード ファーマシューティカルズ インコーポレイテッド |
カルボキサミド化合物、組成物、及びｐａｒｐ活性の抑制方法
|
|
WO2000026193A1
(de)
|
1998-10-30 |
2000-05-11 |
Lonza Ag |
Verfahren zur herstellung von 4-[(2',5'-diamino-6'-halogenpyrimidin-4'-yl)amino]-cyclopent-2-enylmethanolen
|
|
TR200101239T2
(tr)
|
1998-11-03 |
2001-11-21 |
Basf Aktiengesellschaft |
İkameli-2-fenilbenzimidazoller, üretimleri ve kullanımları
|
|
JP2002529537A
(ja)
|
1998-11-17 |
2002-09-10 |
ビーエーエスエフ アクチェンゲゼルシャフト |
２−フェニルベンズイミダゾールおよび２−フェニルインドール、その製造方法ならびに使用
|
|
DK1133477T3
(da)
|
1998-11-27 |
2004-06-21 |
Abbott Gmbh & Co Kg |
Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
|
|
DE19918211A1
(de)
|
1999-04-22 |
2000-10-26 |
Basf Ag |
Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
|
|
DE19920936A1
(de)
|
1999-05-07 |
2000-11-09 |
Basf Ag |
Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
|
|
AU7314200A
(en)
|
1999-09-17 |
2001-04-24 |
Yamanouchi Pharmaceutical Co., Ltd. |
Benzimidazole derivatives
|
|
ES2290115T3
(es)
|
2000-02-01 |
2008-02-16 |
ABBOTT GMBH & CO. KG |
Compuestos heterociclicos y su aplicacion como inhibidores de parp.
|
|
DE10022925A1
(de)
|
2000-05-11 |
2001-11-15 |
Basf Ag |
Substituierte Indole als PARP-Inhibitoren
|
|
WO2002068407A1
(en)
|
2001-02-28 |
2002-09-06 |
Yamanouchi Pharmaceutical Co., Ltd. |
Benzimidazole compound
|
|
JP2003005323A
(ja)
|
2001-06-20 |
2003-01-08 |
Konica Corp |
熱現像写真感光材料及び画像形成方法
|
|
WO2003007959A1
(en)
|
2001-07-16 |
2003-01-30 |
Fujisawa Pharmaceutical Co., Ltd. |
Quinoxaline derivatives which have parp inhibitory action
|
|
KR20040047869A
(ko)
|
2001-09-26 |
2004-06-05 |
파마시아 이탈리아 에스.피.에이. |
키나제 억제제로서 활성인 아미노인다졸 유도체, 이의제조방법 및 이를 함유하는 약제학적 조성물
|
|
WO2003062234A1
(en)
|
2002-01-23 |
2003-07-31 |
Yamanouchi Pharmaceutical Co., Ltd. |
Quinoxaline compounds
|
|
US20040034078A1
(en)
|
2002-06-14 |
2004-02-19 |
Agouron Pharmaceuticals, Inc. |
Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
|
|
JPWO2004014861A1
(ja)
|
2002-08-09 |
2005-12-02 |
杏林製薬株式会社 |
４−置換キノリン−８−カルボン酸アミド誘導体とその薬理上許容される付加塩
|
|
JP2006516254A
(ja)
|
2003-01-06 |
2006-06-29 |
イーライ・リリー・アンド・カンパニー |
Ｐｐａｒモジュレータとしての縮合ヘテロ環誘導体
|
|
AU2004259741A1
(en)
|
2003-07-21 |
2005-02-03 |
Smithkline Beecham Corporation |
(2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof
|
|
WO2005047290A2
(en)
|
2003-11-11 |
2005-05-26 |
Cellular Genomics Inc. |
Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
|
|
GB0327740D0
(en)
|
2003-11-28 |
2003-12-31 |
Glaxo Group Ltd |
Novel compounds
|
|
WO2005066136A1
(en)
|
2003-12-22 |
2005-07-21 |
Eli Lilly And Company |
Bicyclic derivatives as ppar modulators
|
|
CA2568835C
(en)
|
2004-06-30 |
2014-05-27 |
Janssen Pharmaceutica N.V. |
Quinazolinone derivatives as parp inhibitors
|
|
CA2580833C
(en)
|
2004-09-22 |
2010-12-21 |
Pfizer, Inc. |
Method of preparing poly(adp-ribose) polymerases inhibitors
|
|
EP1812439B2
(en)
|
2004-10-15 |
2017-12-06 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
JP3701964B1
(ja)
|
2005-03-08 |
2005-10-05 |
アステラス製薬株式会社 |
キヌクリジン誘導体の新規な塩
|
|
TWI375673B
(en)
|
2005-04-11 |
2012-11-01 |
Abbott Lab |
1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
|
|
US7728026B2
(en)
|
2005-04-11 |
2010-06-01 |
Abbott Laboratories, Inc. |
2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
|
|
CN101316834A
(zh)
|
2005-09-29 |
2008-12-03 |
艾博特公司 |
在2位取代有苯基的1h-苯并咪唑-4-甲酰胺是强效parp抑制剂
|
|
JP5162465B2
(ja)
|
2005-11-15 |
2013-03-13 |
アボット・ラボラトリーズ |
置換１ｈ−ベンズイミダゾール−４−カルボキサミド類は強力なｐａｒｐ阻害薬である
|
|
US20090275619A1
(en)
|
2006-04-03 |
2009-11-05 |
BOUERES Julia |
Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
|
|
MX2008014004A
(es)
|
2006-05-02 |
2008-11-12 |
Abbott Lab |
1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes.
|
|
BRPI0806245B1
(pt)
|
2007-01-10 |
2022-01-25 |
Msd Italia S.R.L. |
Compostos de fórmula i e seus usos
|
|
US20090062268A1
(en)
|
2007-08-27 |
2009-03-05 |
Lead Therapeutics, Inc. |
Novel inhibitors of poly(adp-ribose)polymerase (parp)
|
|
EP2240466B1
(en)
|
2008-01-08 |
2015-07-29 |
Merck Sharp & Dohme Limited |
Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
|
|
CN101998959B
(zh)
|
2008-02-06 |
2013-08-28 |
生物马林药物股份有限公司 |
聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂
|
|
EP2928473B1
(en)
|
2012-12-07 |
2017-06-28 |
Merck Sharp & Dohme Corp. |
Regioselective n-2 arylation of indazoles
|
|
RS61400B1
(sr)
|
2013-05-02 |
2021-02-26 |
Anaptysbio Inc |
Antitela usmerena protiv programirane smrti-1 (pd-1)
|
|
MA41463A
(fr)
|
2015-02-03 |
2017-12-12 |
Anaptysbio Inc |
Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
|
|
PL3277321T3
(pl)
|
2015-04-01 |
2024-11-18 |
Anaptysbio, Inc. |
Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3)
|
|
WO2017218365A1
(en)
*
|
2016-06-16 |
2017-12-21 |
Sunshine Lake Pharma Co., Ltd. |
Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
|
|
HRP20240136T1
(hr)
|
2016-06-29 |
2024-04-12 |
Tesaro, Inc. |
Metode liječenja raka jajnika
|
|
WO2018018354A1
(zh)
*
|
2016-07-25 |
2018-02-01 |
刘文婷 |
超市智能结算购物车及其使用方法
|
|
CN106496187A
(zh)
|
2016-09-14 |
2017-03-15 |
陕西科技大学 |
一种制备PARP抑制剂Niraparib的合成方法
|
|
CN110049777A
(zh)
|
2016-11-01 |
2019-07-23 |
安奈普泰斯生物有限公司 |
针对程序性死亡-1(pd-1)的抗体
|
|
MA50677A
(fr)
|
2016-11-01 |
2021-07-14 |
Anaptysbio Inc |
Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
|
|
CN108201537A
(zh)
|
2016-12-16 |
2018-06-26 |
苏州苏融生物医药有限公司 |
一种尼拉帕尼缓控释药物组合物及其用途
|
|
WO2018122168A1
(en)
|
2016-12-29 |
2018-07-05 |
Bayer Pharma Aktiengesellschaft |
Combinations of bub1 kinase and parp inhibitors
|
|
PT3565844T
(pt)
|
2017-01-09 |
2023-05-02 |
Tesaro Inc |
Métodos de tratamento de cancro com anticorpos anti-pd-1
|
|
AU2018205401B2
(en)
|
2017-01-09 |
2025-01-02 |
Tesaro, Inc. |
Methods of treating cancer with anti-TIM-3 antibodies
|
|
AU2018246214B2
(en)
|
2017-03-27 |
2021-07-08 |
Merck Sharp & Dohme Llc |
Niraparib compositions
|
|
WO2018200517A1
(en)
|
2017-04-24 |
2018-11-01 |
Tesaro, Inc. |
Methods of manufacturing of niraparib
|
|
TWI791519B
(zh)
|
2017-04-27 |
2023-02-11 |
美商提薩羅有限公司 |
針對淋巴細胞活化基因-3（lag-3）之抗體藥劑及其用途
|
|
CN110913911A
(zh)
|
2017-05-18 |
2020-03-24 |
特沙诺有限公司 |
用于治疗癌症的组合疗法
|
|
CN108530425A
(zh)
*
|
2017-05-27 |
2018-09-14 |
广州科锐特生物科技有限公司 |
一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法
|
|
CN108203404A
(zh)
*
|
2018-03-02 |
2018-06-26 |
上海博邦医药科技有限公司 |
(r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法
|
|
US12297184B2
(en)
|
2018-10-03 |
2025-05-13 |
Tesaro, Inc. |
Niraparib salts
|